Sprint Bioscience Equity 2024

Sprint Bioscience Aktienanalyse

What does Sprint Bioscience do?

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sprint Bioscience's Equity

Sprint Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sprint Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sprint Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sprint Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sprint Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sprint Bioscience stock

What is the equity of Sprint Bioscience this year?

Sprint Bioscience has equity of 27.77 M SEK this year.

What was the equity of Sprint Bioscience compared to the previous year?

The equity of Sprint Bioscience has increased/decreased by -1.47% decreased compared to the previous year.

What impact does a high equity have on investors of Sprint Bioscience?

A high equity is advantageous for investors of Sprint Bioscience as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sprint Bioscience?

A low equity can be a risk for investors of Sprint Bioscience, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sprint Bioscience affect the company?

An increase in equity of Sprint Bioscience can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sprint Bioscience affect the company?

A reduction in equity of Sprint Bioscience can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sprint Bioscience?

Some factors that can affect the equity of Sprint Bioscience include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sprint Bioscience so important for investors?

The equity of Sprint Bioscience is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sprint Bioscience take to change the equity?

To change equity, Sprint Bioscience can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sprint Bioscience pay?

Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.

What is the dividend yield of Sprint Bioscience?

The current dividend yield of Sprint Bioscience is .

When does Sprint Bioscience pay dividends?

Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sprint Bioscience?

Sprint Bioscience paid dividends every year for the past 0 years.

What is the dividend of Sprint Bioscience?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sprint Bioscience located?

Sprint Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sprint Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sprint Bioscience from 7/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did Sprint Bioscience pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of Sprint Bioscience in the year 2023?

In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.

In which currency does Sprint Bioscience pay out the dividend?

The dividends of Sprint Bioscience are distributed in SEK.